Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

Por Carlsen, Arne, Omdal, Roald, Leitao, Kristian Øgreid, Isaksen, Kjetil, Hetta, Anne Kristine, Karlsen, Lars Normann, Aabakken, Lars, Bolstad, Nils, Warren, David, Lundin, Knut E.A., Grimstad, Tore
Publicado no Therap Adv Gastroenterol (2018)